RDY · Dr Reddys Laboratories Ltd · Documents
$14.15
+0.40 (+2.91%)
At close · Oct 28
Return incl. dividend (before tax)
Q2 2026 earnings call transcript
Market Cap
$11.73B
Shares
833.07M
Volume · Oct 28
3.41M
Avg daily vol (3M)
2.91M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 6-K | Dr. Reddy's Laboratories Ltd reported audio and video recordings of its October 23, 2026 earnings call, covering unaudited financial results for the quarter and half year ended September 30, 2026. | 2026-10-26 | 2026-10-24 | |
| 6-K | Deloitte Haskins & Sells LLP issued unmodified review conclusions on Dr. Reddy’s Laboratories Limited’s unaudited consolidated and standalone results for the quarter and half year ended September 30, 2026, finding no material misstatement or missing disclosures. | 2026-10-26 | 2026-10-24 | |
| 6-K | Dr. Reddy’s Laboratories Limited appointed Akhil Ravi Head API and Services and Senior Management Personnel and inducted him as a Member of the Management Council effective November 13, 2026. He will continue overseeing Aurigene Pharmaceutical Services Ltd. and is related to Mr. G V Prasad. | 2026-10-23 | — | |
| 6-K | Dr. Reddy’s Laboratories Ltd. reported Q2FY27 revenues of ₹ 86,708 Mn and profit attributable to equity holders of ₹ 9,250 Mn, while certain semaglutide batches were out of specification and measures were under way to resume supplies. | 2026-10-23 | — | |
| 6-K | — | 2026-10-23 | — | |
| 6-K | — | 2026-10-23 | — | |
| 6-K | Dr. Reddy’s Laboratories Ltd. received DCGI approval for Zytorvi® (toripalimab) in India for first-line treatment with cisplatin and paclitaxel of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma. | 2026-10-21 | — | |
| 6-K | Dr. Reddy’s Laboratories Limited said the USFDA inspected its FTO-9 manufacturing facility in Visakhapatnam, Andhra Pradesh, from October 8, 2026, to October 9, 2026, and issued a Form 483 with three observations to address within the stipulated timeline. | 2026-10-14 | — | |
| 6-K | Dr. Reddy’s Laboratories Limited said the United States Food and Drug Administration completed a Pre-Approval Inspection of its FTO-11 facility from October 5, 2026 to October 7, 2026 and issued two observations, which the company will address within the stipulated timeline. | 2026-10-08 | — | |
| 6-K | Dr. Reddy's Laboratories Ltd. will announce results for the quarter and six months ended September 30^th^, 2026 on Friday, October 23^rd^, 2026, followed by an earnings call at 19:30 PM IST / 10:00 AM ET. | 2026-10-07 | — | |
| 6-K | Dr. Reddy’s Laboratories Limited said its step-down wholly owned subsidiary received an IRS transcript dated September 25, 2026 on Oct 2,2026, classifying $32,350.20 as a penalty for misclassifying a Fiscal year reference; it assessed no material impact. | 2026-10-05 | 2026-10-03 | |
| 6-K | Dr. Reddy’s Laboratories Limited will hold a Board meeting on Friday, October 23, 2026 to approve Unaudited Standalone and Consolidated Financial Results for the quarter ending September 30, 2026. Its trading window will be closed from September 24, 2026 to October 25, 2026, both days inclusive. | 2026-09-22 | — | |
| 6-K | Dr. Reddy’s Laboratories Limited announced management’s participation in a Nomura-organized Group Meet in Hyderabad on 25.09.2026, scheduled for 11:00 - 14:00 IST and subject to change. | 2026-09-21 | — | |
| 6-K | — | 2026-09-18 | — | |
| 6-K | — | 2026-09-14 | 2026-09-11 | |
| 6-K | — | 2026-09-10 | — | |
| 6-K | — | 2026-09-10 | — | |
| 6-K | — | 2026-08-26 | — | |
| 6-K | — | 2026-08-17 | 2026-08-14 | |
| 6-K | — | 2026-08-17 | 2026-08-14 | |
| 6-K | — | 2026-08-13 | — | |
| 6-K | — | 2026-08-10 | 2026-08-07 | |
| 6-K | — | 2026-08-03 | 2026-08-01 | |
| 6-K | — | 2026-07-29 | 2026-07-28 | |
| 6-K | — | 2026-07-29 | — | |
| 6-K | — | 2026-07-23 | — | |
| 6-K | — | 2026-07-23 | — | |
| 6-K | — | 2026-07-23 | — | |
| 6-K | — | 2026-07-23 | — | |
| 6-K | — | 2026-07-23 | — | |
| 6-K | — | 2026-07-22 | — | |
| 6-K | — | 2026-07-22 | — | |
| 6-K | — | 2026-07-22 | — | |
| 6-K | — | 2026-07-22 | — | |
| 6-K | — | 2026-07-22 | — | |
| 6-K | — | 2026-07-15 | — | |
| 6-K | — | 2026-07-13 | — | |
| 6-K | — | 2026-07-10 | — | |
| 6-K | — | 2026-07-09 | — | |
| 6-K | — | 2026-07-01 | 2026-06-30 | |
| 6-K | — | 2026-07-01 | — | |
| 6-K | — | 2026-06-30 | — | |
| 6-K | — | 2026-06-30 | — | |
| 6-K | — | 2026-06-30 | — | |
| 6-K | — | 2026-06-26 | 2026-06-25 | |
| 6-K | — | 2026-06-22 | 2026-06-20 | |
| 6-K | — | 2026-06-22 | — | |
| 6-K | — | 2026-06-22 | 2026-06-19 | |
| 6-K | — | 2026-06-15 | 2026-06-13 | |
| 6-K | — | 2026-06-10 | — |
Showing 1–50 of 745 filings
Key facts
CIK
1135951
CUSIP
256135203
13F (30d)
56 filings
51 filers
Visit website
Investor relations